Compare
Retractable Technologies Inc vs Utah Medical Products Inc vs ClearPoint Neuro, Inc. vs Orchestra BioMed Holdings, Inc.
| Latest fiscal year | Retractable Technologies Inc RVP | Utah Medical Products Inc UTMD | ClearPoint Neuro, Inc. CLPT | Orchestra BioMed Holdings, Inc. OBIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $38.27M | $38.52M | $36.97M | $33.48M |
| Revenue growth (YoY) | +15.8% | -5.8% | +17.8% | n/m |
| Gross margin | 0.1% | 57.1% | 61.4% | n/a |
| Operating margin | -55.3% | 29.6% | -65.4% | -154.7% |
| Net margin | -32.8% | 29.3% | -69.1% | -157.4% |
| Net income | -$12.57M | $11.29M | -$25.54M | -$52.70M |
| EPS (Diluted) | -$0.43 | $3.48 | -$0.90 | -$1.11 |
| Operating cash flow | -$7.06M | $14.69M | -$23.93M | -$48.96M |
| Free cash flow | n/a | $14.32M | -$24.45M | -$49.45M |
| Cash & equivalents | $2.59M | $85.76M | $45.92M | $34.69M |
| Total assets | $142.63M | $122.54M | $97.75M | $114.86M |
| Total liabilities | $68.26M | $3.27M | $69.73M | $51.48M |
| Shareholders' equity | $74.38M | $119.27M | $28.02M | $53.57M |
| Return on year-end equity | -16.9% | 9.5% | -91.1% | -98.4% |
| Shares outstanding | 29.94M | 3.19M | 29.37M | 57.03M |
Revenue, most recent five fiscal years
| Fiscal year | Retractable Technologies Inc | Utah Medical Products Inc | ClearPoint Neuro, Inc. | Orchestra BioMed Holdings, Inc. |
|---|---|---|---|---|
| Latest | $38.27M Ended 2025-12-31 | $38.52M Ended 2025-12-31 | $36.97M Ended 2025-12-31 | $33.48M Ended 2025-12-31 |
| 1 year earlier | $33.05M Ended 2024-12-31 | $40.90M Ended 2024-12-31 | $31.39M Ended 2024-12-31 | $2.64M Ended 2024-12-31 |
| 2 years earlier | $43.60M Ended 2023-12-31 | $50.22M Ended 2023-12-31 | $23.95M Ended 2023-12-31 | $2.76M Ended 2023-12-31 |
| 3 years earlier | $94.82M Ended 2022-12-31 | $52.28M Ended 2022-12-31 | $20.55M Ended 2022-12-31 | $3.53M Ended 2022-12-31 |
| 4 years earlier | $188.38M Ended 2021-12-31 | $49.05M Ended 2021-12-31 | $16.30M Ended 2021-12-31 | n/a |